Taysha Gene Therapies Other Non-Current Liabilities 2020-2024 | TSHA
Taysha Gene Therapies other non-current liabilities from 2020 to 2024. Other non-current liabilities can be defined as field containing the sum of all non-current liabilities that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
Taysha Gene Therapies Annual Other Non-Current Liabilities
(Millions of US $) |
| 2023 |
$2 |
| 2022 |
$4 |
| 2021 |
$30 |
| 2020 |
$0 |
| 2019 |
$ |
Taysha Gene Therapies Quarterly Other Non-Current Liabilities
(Millions of US $) |
| 2024-09-30 |
$1 |
| 2024-06-30 |
$1 |
| 2024-03-31 |
$2 |
| 2023-12-31 |
$2 |
| 2023-09-30 |
$4 |
| 2023-06-30 |
$4 |
| 2023-03-31 |
$4 |
| 2022-12-31 |
$4 |
| 2022-09-30 |
$29 |
| 2022-06-30 |
$29 |
| 2022-03-31 |
$29 |
| 2021-12-31 |
$30 |
| 2021-09-30 |
$30 |
| 2021-06-30 |
$27 |
| 2021-03-31 |
$1 |
| 2020-12-31 |
$0 |
| 2020-09-30 |
|
| 2020-06-30 |
|
| 2020-03-31 |
|
| 2019-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.447B |
$0.015B |
|
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
|
